SCHEMBL6263371

SCHEMBL6263371

CC(=O)Oc1ccc(C(=O)Nc2ccc3c(c2)C(=O)NC3=O)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 11/20 0.77
MEN1 O00255 8/20 0.77
CTDSP1 Q9GZU7 1/20 0.70
KDM4E B2RXH2 3/20 0.59
ALDH1A1 P00352 3/20 0.59
RECQL P46063 2/20 0.59
HPGD P15428 1/20 0.59
CASP3 P42574 4/20 0.57
PKM P14618 2/20 0.57
LMNA P02545 1/20 0.57
POLB P06746 1/20 0.57
HTT P42858 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
NPC1 O15118 1/20 0.57
RAB9A P51151 1/20 0.57
RXFP1 Q9HBX9 2/20 0.56
GLA P06280 1/20 0.56
CASP2 P42575 1/20 0.54
CASP7 P55210 1/20 0.54
CASP6 P55212 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6260500 0.87 KMT2A (1.00) KMT2AMEN1CTDSP1ALDH1A1CASP3
SCHEMBL12635981 0.85 KMT2A (1.00) KMT2AMEN1CTDSP1KDM4EALDH1A1
SCHEMBL12635988 0.82 KMT2A (1.00) KMT2AMEN1CTDSP1KDM4EALDH1A1
SCHEMBL22079528 0.81 KMT2A (0.71) KMT2AMEN1CTDSP1KDM4ECASP3
SCHEMBL22625585 0.81 ACE2 (0.67) KMT2AMEN1CTDSP1KDM4EALDH1A1
SCHEMBL6264004 0.81 KMT2A (0.76) KMT2AMEN1CTDSP1KDM4EALDH1A1
SCHEMBL17570205 0.80 KMT2A (0.70) KMT2AMEN1KDM4ERECQLHPGD
SCHEMBL6263607 0.80 RXFP1 (0.75) KMT2AMEN1CTDSP1KDM4EALDH1A1
SCHEMBL6259571 0.80 KMT2A (0.74) KMT2AMEN1CTDSP1KDM4EALDH1A1
SCHEMBL30949343 0.79 KMT2A (0.64) KMT2AMEN1CTDSP1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050182061-A1 Phthalimide compounds useful as protein kinase inhibitors GREEN JEREMY (US) 2005-08-18 US claimed
WO-2005039564-A1 PHTHALIMIDE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-05-06 WO claimed
US-20050182061-A1 Phthalimide compounds useful as protein kinase inhibitors GREEN JEREMY (US) 2005-08-18 US disclosed
WO-2005039564-A1 PHTHALIMIDE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182061-A1 Phthalimide compounds useful as protein kinase inhibitors PDK1, PDPK1, MTOR KMT2A 1256/4885MEN1 1849/4885CTDSP1 2132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.